Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720.

Eitemau Tebyg

• Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication.
  gan: Kleim, J P, et al.
  Cyhoeddwyd: (1993)
• Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1.
  gan: Pelemans, H, et al.
  Cyhoeddwyd: (1997)
• Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication.
  gan: Kleim, J P, et al.
  Cyhoeddwyd: (1995)
• Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants.
  gan: Kleim, J P, et al.
  Cyhoeddwyd: (1996)
• Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants.
  gan: Balzarini, J, et al.
  Cyhoeddwyd: (1994)